Encapsulation of aceclofenac hydrogel-based solid dispersion for sustained delivery
Résumé
Purpose: To develop aceclofenac hydrogel-based solid dispersions (AC-HSDs) encapsulated in two modified gelatin capsules (MGCs as MGX1 and MGX2) for sustained drug delivery.Methods: The AC-HSDs were prepared with Eudragit L 100 (EL1 – EL5) and hydroxypropyl methylcellulose acetate succinate (HP1 – HP5) at various drug: carrier ratios (1:1, 1:2, 2:1, 1:3, using solvent evaporation technique and characterized by percentage encapsulation efficiency (EE%), scanning electron microscopy (SEM), differential scanning calorimetry (DSC). In vitro drug release of 10mg (AC-HSDs) was investigated using USP Type I and in vivo anti-inflammatory study of (AC-HSDs; test), pure aceclofenac, and aceclofenac tablet (positive control; administered orally at 10 mg/kg body) was evaluated using the rat paw edema method.Result: Eudragit–based solid dispersions showed significantly higher entrapment efficiency compared to hydroxypropyl methylcellulose acetate succinate–based formulation (p < 0.05). The DSC and SEM of both batches revealed discrete particle sizes and shapes with decreased crystallinity. The AC-HSDs encapsulated in MGX1 showed significantly prolonged drug release compared to MGX2 (p < 0.05). Furthermore, HP-SDs showed significantly higher edema inhibition (86 %) compared to pureaceclofenac and commercial aceclofenac tablets (p < 0.05)Conclusion: Aceclofenac hydrogel-based solid dispersions (AC-HSDs) encapsulated in MGCs show sustained release effects as an alternative technology to deliver aceclofenac.
Citer ce document
Accès au document
Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter
Voir l'article sur le site de la revueAuteur(s)
Statistiques
Consultations : 1
Téléchargements : 0